Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idebenone versus placebo in glucocorticoid-treated Duchenne muscular dystrophy
NL-OMON50682Phase 3Active, not recruiting
- Sponsor
- Santhera Pharmaceuticals
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of idebenone in Duchenne muscular dystrophy (DMD), sponsored by Santhera Pharmaceuticals. Started Jan 2018; status: active, not recruiting.
02
Drugs
idebenone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON50682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50682.